Circular RNA Breakthrough! Targeting Osteoarthritis, a New Frontier for RNA-Based Protein Replacement Therapy

Osteoarthritis (OA), the most common degenerative joint disease, affects hundreds of millions of people worldwide and represents a major unmet medical challenge. Characterized by progressive cartilage destruction, chronic inflammation, and bone spur formation, osteoarthritis leads to long-term pain, disability, and a significant socioeconomic burden. Despite decades of research, most available therapies only relieve symptoms rather than addressing the root cause of the disease.

Recent advances in circular RNA (circRNA) technology are now opening an entirely new frontier for RNA-based protein replacement therapy. A groundbreaking study published in Nature Communications demonstrated that in vitro transcribed circular RNA (ivcRNA) can effectively restore key proteins involved in cartilage health, providing a potential disease-modifying treatment strategy for osteoarthritis.

Beyond the scientific breakthrough itself, this innovation also highlights the growing importance of biopharmaceutical manufacturing technologies, including bioprocess modules, cell culture systems, purification & filtration platforms, and virus safety solutions, which are essential for translating RNA therapeutics from the laboratory to large-scale clinical production.

Identifying the Key Target in Osteoarthritis

Loss of Msi2 Protein Drives Cartilage Degeneration

The first step toward developing a disease-modifying therapy for osteoarthritis is understanding its molecular drivers. The study revealed that the Musashi2 (Msi2) protein, an RNA-binding protein critical for cellular metabolism and tissue homeostasis, is significantly downregulated in osteoarthritic cartilage.

Through analysis of both human cartilage samples and mouse osteoarthritis models, researchers found that the loss of Msi2 disrupts the metabolic balance of chondrocytes, the specialized cells responsible for maintaining cartilage structure.

Specifically, the absence of Msi2 leads to:

Decreased expression of protective cartilage components such as Collagen II (COL2) and Aggrecan

Increased activity of destructive enzymes such as Matrix Metalloproteinase-13 (MMP13)

This imbalance accelerates cartilage breakdown and joint degeneration, ultimately driving the progression of osteoarthritis.

The identification of Msi2 as a therapeutic target creates an opportunity for RNA-based protein replacement therapy, where functional proteins are reintroduced into cells through RNA delivery. However, achieving stable and efficient protein expression in joint tissues requires more advanced RNA technologies than traditional approaches.

Why Circular RNA is Transforming RNA Therapeutics

Overcoming the Limitations of Conventional mRNA

Traditional mRNA therapeutics gained global recognition during the COVID-19 pandemic, but they still face several limitations when applied to chronic diseases such as osteoarthritis. These include:

Limited stability, leading to rapid degradation

High immunogenicity, which may trigger immune responses

Short protein expression duration, typically lasting only a few days

In contrast, circular RNA (circRNA) offers significant advantages due to its unique molecular structure.

Unlike linear RNA molecules, circRNA forms a covalently closed loop, which protects it from exonuclease degradation. This structure provides several key benefits:

Enhanced molecular stability

Reduced immunogenicity

Longer protein expression duration

No requirement for costly 5’ capping modifications

These characteristics make circular RNA an attractive platform for next-generation RNA therapeutics, particularly in applications requiring sustained protein expression.

For biotechnology companies and pharmaceutical developers, this also creates new demand for advanced bioprocess technologies, including scalable RNA production systems, purification platforms, and high-precision manufacturing equipment compliant with cGMP standards.

Targeted Delivery with Lipid Nanoparticles

Precision Medicine through ivcRNA-LNP Systems

Efficient delivery is a critical factor in the success of RNA-based therapies. To ensure that circular RNA reaches the target cells within the joint, researchers developed a targeted delivery system based on lipid nanoparticles (LNPs).

These LNPs are similar to those used in some COVID-19 vaccines and have already been clinically validated for nucleic acid delivery. In this study, ivcRNA encoding the Msi2 protein was encapsulated within lipid nanoparticles, allowing the RNA molecules to be protected and efficiently transported into chondrocytes.

The treatment was administered through direct intra-articular injection, enabling precise targeting of cartilage tissue.

To further enhance translation efficiency, the researchers incorporated a chondrocyte-specific Internal Ribosome Entry Site (IRES). This design ensured that the circular RNA could be effectively translated into functional proteins specifically within cartilage cells.

Experimental results showed that ivcRNA-mediated protein expression lasted more than seven days, significantly longer than the typical three-day expression period observed with linear mRNA.

Importantly, the expression remained stable even within the inflammatory microenvironment of osteoarthritic joints, demonstrating the robustness of the circular RNA platform.

Promising Results in Preclinical Models

Significant Improvement in Osteoarthritis Symptoms

The therapeutic potential of circular RNA was further validated in a mouse model of osteoarthritis, specifically the destabilization of the medial meniscus (DMM) model.

Following injection of ivcRNA encoding the Msi2 protein, researchers observed several encouraging outcomes:

Reduced cartilage calcification

Decreased cartilage erosion and joint damage

Significant reduction in OARSI (Osteoarthritis Research Society International) scores

These results indicate that restoring Msi2 expression can effectively slow or even reverse cartilage degeneration.

The research team also explored additional therapeutic targets within the same signaling pathway. For example, SOX5, a downstream protein regulated by Msi2, was delivered using ivcRNA technology and demonstrated similarly strong therapeutic effects.

This finding highlights the versatility of circular RNA-based therapies, which can be adapted to deliver different therapeutic proteins depending on disease mechanisms.

Safety Profile and Dosage Advantages

One of the most striking findings of the study was the excellent safety profile of the circular RNA therapy.

Compared with traditional mRNA therapeutics, which often require 5–50 μg doses, the ivcRNA treatment achieved strong efficacy at extremely low doses of only 100–300 ng per injection.

Lower dosage requirements bring several advantages:

Reduced risk of adverse immune reactions

Lower manufacturing costs

Improved patient safety

Importantly, no significant inflammatory responses were observed during the experiments, supporting the potential of circular RNA as a safe therapeutic platform.

Implications for Biopharmaceutical Manufacturing

Growing Demand for Advanced Bioprocess Solutions

While circular RNA therapeutics represent a major scientific breakthrough, their successful commercialization will depend heavily on scalable and compliant biomanufacturing technologies.

Large-scale production of ivcRNA requires sophisticated bioprocess modules covering the entire workflow, including:

Microbial & cell culture systems for RNA production platforms

Media & buffer preparation systems to ensure consistent upstream processing

Clarification & harvest technologies for efficient separation of biomolecules

Purification & filtration solutions to remove impurities and ensure RNA purity

Virus safety systems to meet global biopharmaceutical safety standards

Cleaning & waste inactivation systems for GMP-compliant manufacturing environments

Companies specializing in biopharmaceutical equipment and integrated biotech solutions, such as Shanghai Ritai Medicine Equipment Project Co., Ltd., play a crucial role in enabling these emerging therapies.

With expertise in cGMP-compliant process vessel manufacturing, modular bioprocess lines, and integrated valve-piping systems, Ritai provides full-lifecycle support for biopharmaceutical manufacturers—from facility design and equipment installation to validation and operational training.

These customizable biopharmaceutical process solutions help companies accelerate product development, scale up production, and meet stringent global regulatory standards such as FDA, EU GMP, and PED-CE compliance.

From Laboratory Discovery to Clinical Application

The emergence of circular RNA technology marks a pivotal moment in the evolution of RNA therapeutics. By enabling stable and long-lasting protein expression, circRNA platforms have the potential to transform the treatment of chronic degenerative diseases like osteoarthritis.

However, moving from promising laboratory results to real-world therapies requires not only scientific innovation but also robust bioprocess engineering, scalable manufacturing infrastructure, and strict regulatory compliance.

Through advanced biopharmaceutical process solutions, modular manufacturing platforms, and integrated production systems, the biotechnology industry is now better equipped than ever to support the commercialization of next-generation RNA medicines.

As circular RNA therapies continue to advance toward clinical trials and industrial production, they may ultimately deliver the long-awaited disease-modifying treatment for osteoarthritis, improving the quality of life for millions of patients worldwide while opening a new chapter in the biopharmaceutical industry.